Abstract 2819: Serum parietal cell antibodies, gastrin G17 concentration and risk of gastric cancer: A 15 year prospective assessment

Abstract

Abstract Background: We conducted a prospective nested case-cohort analysis within a high-risk Chinese population to determine if baseline serum PCAs or gastrin was associated with an increased risk of gastric or esophageal cancer during 15 years of follow-up. Methods: The study included 200 cases of gastric cardia adenocarcinoma (GCA), 200 gastric non-cardia adenocarcinomas (GNCA), 100 esophageal squamous cell carcinomas (ESCC), and a 400 person subcohort of the Linxian General Population Nutritional Intervention Trial cohort. Serum PCA and gastrin G17 concentrations were measured using enzyme-linked immunosorbent assays. Mean sample concentrations were calculated by averaging duplicate optical density measures. Cox proportional hazards models were used to estimate crude and adjusted hazard ratios (HRs) and 95% confidence intervals (95% CIs), using case-cohort models. Models assessed high PCA (Q4 vs Q1) or low gastrin G17 (Q1 vs Q4) and cancer risk. H. pylori status and pepsinogen serology were previously determined (Kamangar et al. Br J. Ca 2007, Ren et al. Gut 2009). Results: The average time from baseline to cancer diagnosis was 8.1 years. Serum PCA concentrations were non-significantly lower in those who developed GCA than in the subcohort, and were inversely associated with GCA risk. Serum gastrin G17 concentrations were significantly lower in those who developed GNCA than in the subcohort, and were inversely associated with GNCA risk. Neither serum PCA nor gastrin G17 concentration was associated with ESCC risk. These associations were independent of gender, age, smoking, serum pepsinogen I and II concentrations, and H. pylori status. PCA concentration, median (IQR)PwilcoxonPCA Q4 vs Q1PtrendSubcohort (N= 424)0.84 (0.26-5.8)---ESCC (N=95)1.02 (0.32-6.3)0.231.28 (0.65-2.53)>0.5Cardia (N=193)0.59 (0.23-3.2)0.0700.53 (0.30-0.93)0.013Noncardia (N=193)0.85 (0.27-5.4)0.830.76 (0.42-1.35)>0.5 G17 concentration median (IQR)PwilcoxonG17 Q1 vs Q4PtrendSubcohort (N= 424)3.16 (0.78-8.33)-- ESCC (N=95)3.23 (0.57-10.39)0.731.06 (0.55-2.03)0.91Cardia (N=193)3.23 (0.87-6.89)0.681.54 (0.83-2.87)0.30Noncardia (N=193)2.20 (0.30-5.70)0.00203.72 (1.83-7.57)0.00020 Conclusion: High serum parietal cell antibodies were associated with a decreased risk of GCA, and low serum gastrin G17 levels were associated with an increased risk of GNCA in this high-risk population. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 2819.